Sentinext Therapeutics Sdn Bhd

Bavarian Nordic A/s

Mab Explorations Sdn Bhd

Venture Technologies Sdn Bhd

Mary Jane Cardosa

Mohamad Fakruddin Jamiluddin

Sharifah Binti Hamid

Paul Michael Howley

Sonja Leyrer

Magdeline Sia Henry Sum

This invention provides antibodies or fragments thereof that are capable of specifically binding to at least one conformational epitope of Human Enterovirus 71 (EV71), wherein the antibody individually comprises at least one variable light chain and at least one variable heavy chain. There is also provided a method of producing an antibody capable of specifically binding to at least one conformational epitope of Human Enterovirus 71 (EV71).

Antibodies specific for enteroviruses that infect humans

The instant invention provides materials and methods for producing immunologically active antigens derived from members of the Picornaviridae virus family. The picornavirus antigens of the invention may be in a form for use as a vaccine administered to a subject in a therapeutic treatment or for the prevention of a picornavirus infection. The picornavirus antigens of the invention may be in the form of an immunogenic composition for use in vaccines which are administered for the prevention of aninfection. The instant invention further encompasses immunogenic compositions comprising HumanA, HumanB, HumanC, HumanD antigens and their use in vaccines for the prevention of aninfection.

Antigens and vaccines directed against human enteroviruses

The instant invention provides materials and methods for producing immunologically active antigens derived from members of the Picornaviridae virus family. The picornavirus antigens of the invention may be in a form for use as a vaccine administered to a subject in a therapeutic treatment or for the prevention of a picornavirus infection. The picornavirus antigens of the invention may be in the form of an immunogenic composition for use in vaccines which are administered for the prevention of aninfection. The instant invention further encompasses immunogenic compositions comprisingA,B,C,D antigens and their use in vaccines for the prevention of aninfection.

This invention provides antibodies or fragments thereof that are capable of specifically binding to at least one conformational epitope of71 (EV71), wherein the antibody individually comprises at least one variable light chain and at least one variable heavy chain. There is also provided a method of producing an antibody capable of specifically binding to at least one conformational epitope of71 (EV71).

The present invention relates to NS1 proteins or parts thereof of Flaviviruses, in particular of Dengue viruses useful for vaccination against said Flavivirus and against one or more other Flaviviruses. The invention further concerns the NS1 protein or parts thereof of one Dengue virus serotype, in particular serotype 2, useful for vaccination against Dengue viruses from all serotypes. The invention further concerns DNA comprising an expression cassette coding for a Flavivirus NS1 or parts thereof, vectors comprising said DNA and vaccines containing or expressing a Flavivirus NS1.

Growing community of inventors

Georgetown, Malaysia

Mary Jane Cardosa